The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
General Electric Company, In the Matter of
General Electric was permitted to acquire InVision Technologies, Inc. with conditions that it divest InVision's YXLON x-ray nondestructive testing and inspection equipment to a Commission approved acquirer. According to the complaint issued with the consent order, the two firms are direct competitors in a highly concentrated market. The consent order protects competition in the United States market for specialized x-ray testing and inspection including standard x-ray cabinets; x-ray systems equipped with automated defect recognition software; and high-energy x-ray generators.
In the Matter of Kentucky Household Goods Carriers Association, Inc. - Sunshine Meeting Notice
Children's Online Privacy Protection Rule - 16 CFR Part 312
20050472: FMR Corp; Fiserv Inc.
20050468: Yucaipa One-Stop Partners, L.P.; Source Interlink Companies, Inc.
20050467: Source Interlink Companies, Inc.; Yucaipa One-Stop Partners, L.P.
20050441: Moulin International Holdings Limited; ECCA Holdings Corporation
20050440: GGC Investment Fund II, L.P.; ECCA Holdings Corporation
20050435: MTC Technologies; Dr. Paul Hsu and Majes Hsu
20050424: Moulin International Holdings Limited; Thomas H. Lee Equity Fund IV, L.P.
20050439: UBS AG; Julius Baer Holding Ltd.
20050426: Highmark, Inc.; Harvey Ross
West Coast Advertising & Marketing, Inc.; et al.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice of Intent to Request Public Comments - 16 CFR Chapter 1
0501003 Informal Interpretation
Cephalon, Inc., and CIMA Labs, Inc.
The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order required Cephalon to grant Barr Laboratories, Inc. a fully paid, irrevocable license to make and sell a generic version of Cephalon's breakthrough cancer pain drug, Actiq, in the United States.